^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay

    Company:
    Thermo Fisher Scientific
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    3ms
    Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients. (PubMed, Cancer Treat Res Commun)
    Despite limited numbers, our study supports the role of front-line LB for improving management of symptomatic patients with lung cancer, potentially leading to early targeted therapy initiation.
    Journal • Liquid biopsy • Biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
    3ms
    Role of Liquid Biopsy in Non–Small Cell Lung Cancer: Experience at a Tertiary Care Center in India (CAP 2024)
    Liquid biopsy is a potential technique in diagnosis and treatment monitoring of non–small cell lung cancer where tissue samples are not available for testing. It is emerging as an effective tool in patient management.Spectrum of Mutations in Liquid Biopsy
    Liquid biopsy • Biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
    over1year
    MARTINI: Minimal Residual Disease: A Trial Using Liquid Biopsies in Solid Malignancies. (clinicaltrials.gov)
    P=N/A; Recruiting --> Active, not recruiting
    Enrollment closed • Liquid biopsy • Minimal residual disease • Biopsy
    |
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
    over2years
    Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients (ESMO 2022)
    Conclusions Front-line liquid biopsy might improve the management of symptomatic, hospitalized patients with lung cancer, potentially leading to early start of targeted therapy. Enrollment and longitudinal monitoring of oncogenic drivers with liquid biopsy are ongoing.
    Clinical • Liquid biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • EGFR exon 19 deletion • ALK rearrangement
    |
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay • Oncomine™ Lung cfDNA Assay
    over2years
    Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. (PubMed, Clin Oncol (R Coll Radiol))
    "This study shows the wide spectrum of primary and secondary EGFR resistance mechanisms to first, second and third generation of TKIs and helps us to identify newer therapeutic targets that could carry forward the initial advantage offered by EGFR TKIs."
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    KRAS mutation • EGFR mutation • PIK3CA mutation • EGFR L858R • MET amplification • EGFR T790M • EGFR amplification • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • MET mutation • ALK translocation • EGFR exon 20 mutation • EGFR T790M + EGFR C797S • EGFR negative • EGFR E709A
    |
    therascreen® EGFR RGQ PCR Kit • Oncomine Focus Assay • Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib
    over2years
    Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience (IASLC-WCLC 2022)
    A high positivity rate of detection of actionable and prognostic genomic alterations in the liquid biopsy has established the importance of blood as an important resource of detecting mutations in advanced NSCLC which directly impacts the clinical outcome in these patients. Furthermore, presence of co-positivity of mutations highlights the biologic mechanisms responsible for drug resistance in NSCLC patients.
    Clinical • Liquid biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • NRAS mutation • PIK3CA mutation • BRAF V600 • EGFR L858R • EGFR T790M • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • EGFR positive • EGFR mutation + PIK3CA mutation • ALK rearrangement + PIK3CA mutation
    |
    Oncomine Lung Cell-Free Total Nucleic Acid Research Assay